These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12490774)

  • 21. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients.
    Barak Y; Shamir E; Zemishlani H; Mirecki I; Toren P; Weizman R
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1199-202. PubMed ID: 12452546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
    Breier A; Hamilton SH
    Biol Psychiatry; 1999 Feb; 45(4):403-11. PubMed ID: 10071708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial.
    Berk M; Brook S; Trandafir AI
    Int Clin Psychopharmacol; 1999 May; 14(3):177-80. PubMed ID: 10435771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
    Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
    Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects.
    Kiang M; Daskalakis ZJ; Christensen BK; Remington G; Kapur S
    J Psychiatry Neurosci; 2003 Jul; 28(4):293-9. PubMed ID: 12921224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
    Peuskens J; Gillain B; De Graeve D; Van Vleymen B; Albert A
    Eur Psychiatry; 2009 Apr; 24(3):154-63. PubMed ID: 19118983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comment: risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
    Lu ML; Shen WW
    Ann Pharmacother; 2002; 36(7-8):1292; author reply 1292-3. PubMed ID: 12086567
    [No Abstract]   [Full Text] [Related]  

  • 30. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
    Nasrallah HA; Brecher M; Paulsson B
    Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
    Beasley CM; Dellva MA; Tamura RN; Morgenstern H; Glazer WM; Ferguson K; Tollefson GD
    Br J Psychiatry; 1999 Jan; 174():23-30. PubMed ID: 10211147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.
    Gómez JC; Sacristán JA; Hernández J; Breier A; Ruiz Carrasco P; Antón Saiz C; Fontova Carbonell E
    J Clin Psychiatry; 2000 May; 61(5):335-43. PubMed ID: 10847307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
    Leucht S; Pitschel-Walz G; Abraham D; Kissling W
    Schizophr Res; 1999 Jan; 35(1):51-68. PubMed ID: 9988841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.
    Hill AL; Sun B; McDonnell DP
    Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):216-22. PubMed ID: 23428782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study.
    Alvarez E; Bobes J; Gómez JC; Sacristán JA; Cañas F; Carrasco JL; Gascón J; Gibert J; Gutiérrez M;
    Eur Neuropsychopharmacol; 2003 Jan; 13(1):39-48. PubMed ID: 12480121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
    Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
    Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
    Sacristán JA; Gómez JC; Montejo AL; Vieta E; Gregor KJ
    Clin Ther; 2000 May; 22(5):583-99. PubMed ID: 10868556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.